BRPI0917819B8 - compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado - Google Patents
compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugadoInfo
- Publication number
- BRPI0917819B8 BRPI0917819B8 BRPI0917819A BRPI0917819A BRPI0917819B8 BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8 BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 A BRPI0917819 A BR PI0917819A BR PI0917819 B8 BRPI0917819 B8 BR PI0917819B8
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- pharmaceutical formulation
- drug
- derivative compounds
- carbonate derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18975108P | 2008-08-22 | 2008-08-22 | |
US61/189751 | 2008-08-22 | ||
PCT/US2009/054595 WO2010022320A2 (en) | 2008-08-22 | 2009-08-21 | Polymeric benzyl carbonate-derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0917819A2 BRPI0917819A2 (pt) | 2015-11-24 |
BRPI0917819B1 BRPI0917819B1 (pt) | 2020-11-10 |
BRPI0917819B8 true BRPI0917819B8 (pt) | 2021-05-25 |
Family
ID=41531695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0917819A BRPI0917819B8 (pt) | 2008-08-22 | 2009-08-21 | compostos derivados poliméricos de benzil carbonato, conjugado de droga, formulação farmacêutica, e, uso de um conjugado |
Country Status (12)
Country | Link |
---|---|
US (2) | US8653131B2 (pt) |
EP (1) | EP2328619B1 (pt) |
JP (1) | JP5731385B2 (pt) |
KR (1) | KR101660059B1 (pt) |
AU (1) | AU2009282747B2 (pt) |
BR (1) | BRPI0917819B8 (pt) |
CA (1) | CA2731184C (pt) |
DK (1) | DK2328619T3 (pt) |
ES (1) | ES2617868T3 (pt) |
MX (1) | MX2011001887A (pt) |
NZ (1) | NZ591045A (pt) |
WO (1) | WO2010022320A2 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
JP7022328B2 (ja) * | 2017-03-30 | 2022-02-18 | 日油株式会社 | 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体 |
CN114174307A (zh) * | 2019-07-30 | 2022-03-11 | 松本精密化学株式会社 | 含有异氰酸硅化合物的组合物及其制造方法 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3960871A (en) | 1971-12-27 | 1976-06-01 | Sharps Associates | Esters of thienobenzopyrans and thiopyranobenzopyrans |
US3991194A (en) | 1971-12-27 | 1976-11-09 | Sharps Associates | Heterocyclic esters of benzopyranopyridines |
US4042694A (en) | 1972-12-04 | 1977-08-16 | Sharps Associates | Novel heterocyclic esters of benzopyranopyridines |
US4081449A (en) | 1973-04-05 | 1978-03-28 | Abbott Laboratories | Heterocyclic esters of alkylphenyl benzopyranopyridines |
US4025630A (en) | 1973-09-19 | 1977-05-24 | Abbott Laboratories | Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication |
US3972880A (en) | 1974-03-05 | 1976-08-03 | Sharps Associates | Morpholine containing esters of thienobenzopyrans and thiopyranobenzopyrans |
US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
CA1102337A (en) | 1976-02-13 | 1981-06-02 | Miguel A. Ondetti | Proline derivatives and related compounds |
CA1103255A (en) | 1976-02-13 | 1981-06-16 | Miguel A. Ondetti | Proline derivatives and related compounds |
CA1103257A (en) | 1976-02-13 | 1981-06-16 | Miguel A. Ondetti | Proline derivatives and related compounds |
CA1103256A (en) | 1976-02-13 | 1981-06-16 | Miguel A. Ondetti | Proline derivatives and related compounds |
US4046889A (en) | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
AU509899B2 (en) | 1976-02-13 | 1980-05-29 | E.R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
JPS52136102A (en) | 1976-05-10 | 1977-11-14 | Hoffmann La Roche | Optically active tertiary aliphatic compound |
MTP837B (en) | 1977-11-07 | 1979-10-22 | Hoffman La Roche And Co Aktien | Derivatives 2 finino-imidazolidire |
JPS57192323A (en) | 1981-05-18 | 1982-11-26 | Nisshin Flour Milling Co Ltd | Isoprenyl ether derivative |
US4439364A (en) * | 1982-09-01 | 1984-03-27 | E. I. Du Pont De Nemours & Company | Process for preparing antihypertensive 1-substituted cyclic lactam-2-carboxylic acids and their derivatives |
WO1988003137A1 (en) | 1986-10-28 | 1988-05-05 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists |
US4975438A (en) | 1987-07-10 | 1990-12-04 | Hoffmann-La Roche Inc. | Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor |
US4916145A (en) | 1987-07-10 | 1990-04-10 | Hoffmann-La Roche Inc. | Substituted n-[(pyridyl)alkyl]aryl-carboxamide |
US4927826A (en) | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Cycloproylpropenamides useful as platelet activing factor (PAF) antagonists |
US4788206A (en) | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
US4786646A (en) | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
US4927838A (en) | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
NZ225307A (en) | 1987-07-10 | 1991-06-25 | Hoffmann La Roche | Heterocyclic containing alkene derivatives and pharmaceutical compositions |
US4970210A (en) | 1987-07-17 | 1990-11-13 | Abbott Laboratories | Triazinone lipoxygenase compounds |
US5086052A (en) | 1987-07-17 | 1992-02-04 | Abbott Laboratories | Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity |
DE3734751A1 (de) | 1987-10-14 | 1989-05-03 | Basf Ag | Zwischenprodukte und verfahren fuer die herstellung von sexualpheromonen von miniermotten |
DE3821540A1 (de) | 1988-06-25 | 1989-12-28 | Boehringer Mannheim Gmbh | Neue sulfonamide, verfahren zu ihrer herstellung sowie solche sulfonamide enthaltende arzneimittel |
SE8900685D0 (sv) | 1989-02-28 | 1989-02-28 | Astra Ab | New compounds |
DE3925256A1 (de) | 1989-07-29 | 1991-01-31 | Basf Ag | Substituierte 3-oxypropionsaeure-tert.-butylester |
US5204463A (en) | 1989-08-10 | 1993-04-20 | Glaxo Inc. | Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities |
US5096904A (en) | 1989-09-01 | 1992-03-17 | Glaxo Inc. | Pyridazinones having cardiotonic and beta blocking activities |
US5053338A (en) | 1989-09-01 | 1991-10-01 | Glaxo Inc. | Kinetic resolution of pyridazinones using lipase |
JP2791001B2 (ja) | 1990-02-16 | 1998-08-27 | 株式会社ディ・ディ・エス研究所 | グリコシル−蛋白誘導体 |
JPH085914B2 (ja) | 1990-02-16 | 1996-01-24 | 株式会社ディ・ディ・エス研究所 | グリコシル−蛋白誘導体 |
JP2648584B2 (ja) | 1990-02-16 | 1997-09-03 | 株式会社ディ・ディ・エス研究所 | グリコシル−蛋白誘導体 |
JP2589435B2 (ja) | 1991-09-17 | 1997-03-12 | 株式会社ディ・ディ・エス研究所 | 糖修飾ポリリジン誘導体 |
ATE174916T1 (de) | 1992-03-18 | 1999-01-15 | Takeda Chemical Industries Ltd | Imidazopyridazine als antiasthmatika |
GB9600344D0 (en) | 1996-01-09 | 1996-03-13 | Lilly Co Eli | Benzimidzolyl neuropeptide y receptor antagonists |
CA2242579A1 (en) | 1996-01-09 | 1997-07-17 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
CA2287993A1 (en) | 1997-04-30 | 1998-11-05 | Mary George Johnson | Antithrombotic agents |
CA2287901A1 (en) | 1997-04-30 | 1998-11-05 | Jefferson Ray Mccowan | Antithrombotic agents |
US6284756B1 (en) | 1998-04-30 | 2001-09-04 | Eli Lilly And Company | Antithrombotic agents |
JP4211099B2 (ja) | 1998-11-09 | 2009-01-21 | 三菱化学株式会社 | 透明導電性積層シートの製造方法 |
US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
WO2001046291A1 (en) * | 1999-12-22 | 2001-06-28 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
CN101426763A (zh) | 2000-10-11 | 2009-05-06 | 埃斯佩里安医疗公司 | 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物 |
EP1235294A3 (en) | 2001-02-22 | 2005-06-22 | Fuji Photo Film Co., Ltd. | Electrolyte composition, method for producing the same and non-aqueous electrolyte secondary cell |
US20050020694A1 (en) | 2001-10-11 | 2005-01-27 | Dasseux Jean-Louis Henri | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
JP2005537266A (ja) | 2002-07-12 | 2005-12-08 | バイオマリン ファーマシューティカル インコーポレイテッド | 加水分解性活性物質であるバイオポリマーコンジュゲートを作製するためのイソシアネートリンカーの使用 |
EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US20090181966A1 (en) | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
JP4490413B2 (ja) | 2003-01-06 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | チオール選択的水溶性ポリマー誘導体 |
JP2006518738A (ja) | 2003-02-12 | 2006-08-17 | トランス テック ファーマ,インコーポレイテッド | 治療薬としての置換アゾール誘導体 |
CN102139114A (zh) * | 2003-02-26 | 2011-08-03 | 尼克塔治疗公司 | 聚合物-因子viii部分缀合物 |
US7332164B2 (en) * | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
AU2003902860A0 (en) | 2003-06-06 | 2003-06-26 | Daicel Chemical Industries, Ltd | Benzimidazole compounds |
US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
WO2005068418A1 (en) | 2003-12-24 | 2005-07-28 | Esperion Therapeutics, Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
MXPA06011540A (es) | 2004-04-07 | 2007-01-26 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
FR2875805B1 (fr) | 2004-09-27 | 2006-12-29 | Genfit S A | Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations |
WO2006076471A2 (en) | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
CN100381420C (zh) | 2005-03-23 | 2008-04-16 | 于勇海 | 一种n-乙酰基半胱氨酸衍生物与应用 |
WO2006104884A2 (en) | 2005-03-28 | 2006-10-05 | Shell Internationale Research Maatschappij B.V. | Conversion of alkylhalides into alcohol alkoxylates |
WO2006104883A1 (en) | 2005-03-28 | 2006-10-05 | Shell Internationale Research Maatschappij B.V. | Formation of heteroatom containing derivatives of paraffins |
JP2006327984A (ja) | 2005-05-26 | 2006-12-07 | Fujifilm Holdings Corp | ヘテロ二官能性オリゴエチレングリコールの合成方法及びこれを用いたバイオセンサーの製造方法 |
EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
AU2007219509A1 (en) | 2006-01-18 | 2007-09-07 | Siena Biotech S.P.A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
JP4975353B2 (ja) | 2006-04-07 | 2012-07-11 | ジェイカムアグリ株式会社 | 被覆粒状植物活性物質 |
JP4970257B2 (ja) | 2006-07-27 | 2012-07-04 | 三菱電機株式会社 | エレベータ装置 |
AU2007296054B2 (en) * | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
WO2008082669A2 (en) * | 2006-12-27 | 2008-07-10 | Nektar Therapeutics Al, Corporation | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
JO2686B1 (en) | 2007-04-19 | 2013-03-03 | جلاكسو جروب ليمتد | Vehicles |
WO2009011285A1 (ja) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
CN101965195A (zh) | 2008-03-05 | 2011-02-02 | 巴克斯特国际公司 | 用于药物投送的组合物和方法 |
JP5222187B2 (ja) | 2009-03-12 | 2013-06-26 | 株式会社クボタ | 有孔ブロックおよび有孔ブロックを備えた集水設備の施工方法 |
US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
-
2009
- 2009-08-21 US US12/545,406 patent/US8653131B2/en active Active
- 2009-08-21 CA CA2731184A patent/CA2731184C/en active Active
- 2009-08-21 DK DK09791780.1T patent/DK2328619T3/en active
- 2009-08-21 JP JP2011524025A patent/JP5731385B2/ja active Active
- 2009-08-21 NZ NZ591045A patent/NZ591045A/xx unknown
- 2009-08-21 KR KR1020117006404A patent/KR101660059B1/ko active IP Right Grant
- 2009-08-21 AU AU2009282747A patent/AU2009282747B2/en active Active
- 2009-08-21 ES ES09791780.1T patent/ES2617868T3/es active Active
- 2009-08-21 EP EP09791780.1A patent/EP2328619B1/en active Active
- 2009-08-21 MX MX2011001887A patent/MX2011001887A/es active IP Right Grant
- 2009-08-21 BR BRPI0917819A patent/BRPI0917819B8/pt active IP Right Grant
- 2009-08-21 WO PCT/US2009/054595 patent/WO2010022320A2/en active Application Filing
-
2014
- 2014-01-13 US US14/153,641 patent/US8962549B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2012500804A (ja) | 2012-01-12 |
BRPI0917819A2 (pt) | 2015-11-24 |
EP2328619B1 (en) | 2016-12-07 |
NZ591045A (en) | 2013-01-25 |
US20140128445A1 (en) | 2014-05-08 |
BRPI0917819B1 (pt) | 2020-11-10 |
US8962549B2 (en) | 2015-02-24 |
JP5731385B2 (ja) | 2015-06-10 |
WO2010022320A2 (en) | 2010-02-25 |
WO2010022320A3 (en) | 2010-08-19 |
ES2617868T3 (es) | 2017-06-20 |
KR101660059B1 (ko) | 2016-09-26 |
CA2731184C (en) | 2017-03-21 |
US20100048483A1 (en) | 2010-02-25 |
US8653131B2 (en) | 2014-02-18 |
CA2731184A1 (en) | 2010-02-25 |
MX2011001887A (es) | 2011-04-04 |
AU2009282747B2 (en) | 2015-04-02 |
DK2328619T3 (en) | 2017-03-13 |
EP2328619A2 (en) | 2011-06-08 |
KR20110055681A (ko) | 2011-05-25 |
AU2009282747A1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1125300T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου | |
CY1121860T1 (el) | Συνθετικα ενδιαμεσα για την παρασκευη συζευγματων ολιγοσακχαριτη-πρωτεϊνης | |
BRPI0910746B8 (pt) | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica | |
IL244812A0 (en) | 6-ethyl, 23-methyl-cholic acid, its conjugates with glycine and taurine and pharmaceutical preparations containing them | |
BRPI0905733A2 (pt) | "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica" | |
ECSP13011139A (es) | Anticuerpos contra la angiopoyetina 2 humana | |
BRPI0916877A2 (pt) | composição farmacêutica e administração da mesma | |
BR112012026801B8 (pt) | conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento | |
BR112013007577A2 (pt) | conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado | |
CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
WO2009133352A3 (en) | Lipid composition | |
SV2009003335A (es) | Formulaciones para el cancer | |
NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
UY30319A1 (es) | Formulaciones de inhibidores de dpp iv | |
BRPI0915284A2 (pt) | Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral | |
BRPI0617294B8 (pt) | composição farmacêutica em gel hidroalcóolico e uso de testosterona | |
BRPI0908596A2 (pt) | formulação e composição farmacêutica de liberação prolongada | |
CL2010001422A1 (es) | Uso de dronedarona para la preparacion de un medicamento util en la prevencion de la fibrilacion/aleteo auricular permanente | |
BR112012003283A2 (pt) | sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente. | |
BRPI0916936A2 (pt) | composições faramacêuticas e métodos para produzir baixas concentrações de impureza da mesmas. | |
BRPI0809656A2 (pt) | Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica | |
BRPI0814666A2 (pt) | composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida | |
BRPI0917502A2 (pt) | composição farmacêtica, e, métodos para usar um ácido orgânico ou um antioxidante, para evitar a descoloração causada quando ácido tranemaxâmico e ácido ascórbico são incorporados em uma mesma composição, e para produzir uma preparação farmacêutica sólida para administração oral | |
TR200904159A1 (tr) | Değiştirilmiş salım sağlayan emoksipin formülasyonları. | |
WO2008081829A1 (ja) | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/405 (2006.01), A61K 47/60 (2017.01), A61P |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25A | Requested transfer of rights approved |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) |